42.9205.25% ( -2.380 )
Delay Closed: Nov 20, 16:08:00Valuation
Current ValuationThe current P/E ratio is 27.53, below the reasonable range, cheaper than 99.62% of the time in the past 1 years, and the industry ranks 28/54, the industry Median 7.34.
27.53xP/E
HK$42.92Stock price
HK$1.56Earnings per share
27.53xP/E
Stock priceHK$42.92Earnings per shareHK$1.56
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 44.28x
- Typical range
- 35.81x–56.88x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 7.34x
09182736
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 7.34x
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
01276HKHENGRUI PHARMA | 27.53x | 22.18% | HK$284.87B |
03692HKHANSOH PHARMA | 24.24x | 23.06% | HK$186.41B |
06821HKAsymchem | 27.20x | 27.07% | HK$37.53B |
03933HKUNITED LAB | 21.85x | 55.30% | HK$13.57B |
09989HKHEPALINK | 25.15x | 18.84% | HK$5.56B |
06996HKANTENGENE-B | 27.22x | 246.19% | HK$1.68B |
03737HKZHONGZHIPHARM | 26.60x | -- | HK$539.75M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
